Please use this identifier to cite or link to this item:
Title: Guillain-Barré syndrome in association with antitumour necrosis factor therapy: a case of mistaken identity
Austin Authors: Patwala, Kurvi;Crump, Nicholas H ;De Cruz, Peter
Affiliation: Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
Department of Neurology, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, The University of Melbourne, Melbourne, Australia
Issue Date: 5-Jul-2017 2017-07-05
Publication information: BMJ Case Reports 2017; online first: 5 July
Abstract: Guillain-Barré syndrome (GBS) is an immune-mediated disease characterised by evolving ascending limb weakness, sensory loss and areflexia. Two-thirds of GBS cases are associated with preceding infection. However, GBS has also been described in association with antitumour necrosis factor (TNF) therapies including infliximab and adalimumab for chronic inflammatory disorders such as rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. We present the case of a patient who developed GBS while undergoing treatment with adalimumab in combination with azathioprine for severe fistulising Crohn's disease, and review the literature on neurological adverse events that occur in association with anti-TNF therapy. We also propose an approach to the optimal management of patients who develop debilitating neurological sequelae in the setting of anti-TNF therapy.
DOI: 10.1136/bcr-2017-219481
Journal: BMJ Case Reports
PubMed URL:
Type: Journal Article
Subjects: Contraindications and precautions
Gastrointestinal system
Inflammatory bowel disease
Neurology (drugs and medicines)
Peripheral nerve disease
Type of Clinical Study or Trial: Case Series and Case Reports
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jan 30, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.